Occult brain metastases in HER2-positive breast cancer patients: Frequency and response to radiotherapy [1]

Acta Oncologica

Volumn 46, Issue 7, 2007, Pages 1027-1029

  Niwińska, Anna ^a   Tacikowska, Małgorzata ^a   Pieńkowski, Tadeusz ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYTOSTATIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NAVELBINE; PACLITAXEL; TRASTUZUMAB;

ADULT; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DISEASE COURSE; DISEASE SEVERITY; HUMAN; LETTER; LIVER METASTASIS; LUNG METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; TREATMENT RESPONSE; TUMOR VOLUME;

BRAIN NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; INCIDENCE; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; PILOT PROJECTS; POLAND; RADIATION TOLERANCE; RECEPTOR, ERBB-2;

EID: 35148891337     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860701316099     Document Type: Letter

References (10)

1. Lai R, Dang CT, Malkin MG. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 2004;101:810-6.
2. Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003;97:2972-7.
3. Shmueli E, Wigler N, Inbar M. Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment. Eur J Cancer 2004;40: 379-82.
4. Herrero A, Grandez R, Puertolas T, Orduna VA, Trufero JM, Cid RP, et al. High incidence of brain metastases at the time of death in women with metastatic breast cancer treated with trastuzumab. Proc Am Soc Clin Oncol 2004;23: 67 (abs 765).
5. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 from metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
6. Yau T. Brain as a sanctuary site for early relapse in patients with advanced breast cancer treated with trastuzumab. Breast 2005;14(Suppl 1):S43, (abs P101).
7. Lai RK, Dang C, Thaler H, Malkin M. The incidence of brain metastases in HER2/neu+ stage IV breast cancer patients. Proc Am Soc Clin Oncol 2001;20:66b, (abs 2014).
8. Wardley AM, Danson S, Clayton AJ, Clemons M, Burt P, Stewart A, et al. High incidence of brain metastases in patients treated with trastuzumab for metastatic breast cancer at a large cancer center. Proc Am Soc Clin Oncol 2002;21:61a, (abs 241).
9. Weitzen R, Zach L, Kaufman B, Tichler T, Rath P, Pfeffer J, et al. High incidence of brain metastasis (BM) in patients on trastuzumab (H) for advanced breast cancer. Proc Am Soc Clin Oncol 2002;21:31b, (abs 1936).
10. Altaha R, Crowell E, Hobbs G, Higa G, Abraham J. Increased risk of brain metastases in patients with HER-2/neu-positive breast carcinoma. Cancer 2005;103:442-3.